ABBV Institutional Ownership

AbbVie Inc.

Latest close $246.04 as of Aug 7, 2026

ABBV institutional ownership at a glance

Follow AbbVie Inc. institutional ownership through recent Schedule 13G and 13D filings. Compare reported shares, ownership percentages, filing dates, and changes in beneficial ownership over time.

Latest filing: BlackRock filed Schedule 13G amendment on Jan 25, 2024, reporting 143.2M shares and 8.10% beneficial ownership.

Browse recent ownership filings How Schedule 13G works Why a 13G is not a trade report

How to read Schedule 13 ownership changes

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.

Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.

Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

This gauge summarizes recent agreement across tracked institutional activity.

Latest filing Jan 25, 2024

Public consensus preview Accumulation leaning 61/100 institutional research score

1 tracked institution Latest filing Jan 25, 2024

1 accumulating across 1 comparable institution.

Accumulating1

Unchanged0

Reducing0

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week range data is not available for this security yet.

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Dec 31, 2023

BlackRock Jan 25, 2024 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists, portfolio tools, and the first live gauge on the default tracker. Investor or Pro reveals research gauges across tracker views and unlocks the detailed research above.

Beneficial ownership filing history

Showing 2 of 2 filing(s)

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
BlackRock CIK0001364742	Dec 31, 2023 observed Jan 25, 2024 filed · 25d Schedule 13G amendment	Reported accumulation	143.2M +4.5M	8.10% +0.30 pts	$154.97	$165.13	$246.04
BlackRock CIK0001364742	Dec 31, 2022 observed Feb 16, 2023 filed · 47d Schedule 13G amendment	Earliest Schedule 13G amendment found	138.7M	7.80%	$161.61	$149.53	$246.04

Explore more institutional activity

Related research

Compare ABBV with other securities showing similar institutional activity or recent accumulation across several tracked institutions.

Similar institutional activity

RLAY Relay Therapeutics, Inc. 61/100 Accumulation leaning MIRM MIRUM PHARMACEUTICALS INC 61/100 Accumulation leaning UCB UNITED COMMUNITY BANKS INC 61/100 Accumulation leaning CHTR CHARTER COMMUNICATIONS INC-A 61/100 Accumulation leaning

Recent multi-institution accumulation

OCGN OCUGEN INC 2 accumulating Aug 7, 2026 DNTH Dianthus Therapeutics, Inc. /DE/ 2 accumulating Aug 7, 2026 SRPT Sarepta Therapeutics, Inc. 2 accumulating Aug 7, 2026 RARE ULTRAGENYX PHARMACEUTICAL IN 2 accumulating Aug 7, 2026